UNITY Biotechnology to Present Preclinical Data on Clinical Candidate Molecule UBX1325 at the Association for Research in Vis...
April 28 2021 - 8:00AM
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology
company developing therapeutics to slow, halt or reverse diseases
of aging, will present preclinical data on its lead clinical
candidate, UBX1325, at the Association for Research in Vision and
Ophthalmology (ARVO) 2021 Annual Meeting, being held May 1-7, 2021.
In addition, Przemyslaw (Mike) Sapieha, Ph.D., chief scientific
advisor for UNITY, will participate in a special interest panel on
diabetic retinopathy.
“The data presented at ARVO 2021 highlights the
promising potential of selectively targeting senescent cells to
restore healthy retinal vasculature in patients with diabetic
retinopathies,” said Jamie Dananberg, M.D., chief medical officer
of UNITY. “We continue to build upon the strong scientific
foundation in support of our cellular senescence platform and
Bcl-xL inhibition in ophthalmologic disease, which represents a
promising and much needed alternative to standard of care anti-VEGF
therapies.”
Details of the presentations are as follows:
Panel Discussion Title: Ischemia and
neuronal loss: neglected pathways of vision loss in Diabetic
RetinopathySession: Special Interest
GroupsDate & Time: Wednesday, May 5 at 2:00 –
3:30 pm PT Participant: Przemyslaw (Mike)
Sapieha, Ph.D., chief scientific advisor at UNITY
Presentation Title: UBX1325, a small
molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in
two animal models of
retinopathySession: Diabetic
retinopathy/retinal pharmacology/physiologyDate &
Time: Sunday, May 2 between 6:00 – 7:45 am PT
Presenter: Pamela Tsuruda, Ph.D., senior
director at UNITY
Presentation Title: Inhibition of Bcl-xL
with the small molecule UBX1967 targets Col1a1-positive endothelial
cells in ischemic
retinopathySession: Diabetic retinopathy
Date & Time: Sunday, May 2 between
8:15 – 9:45 am PT Presenter: Sergio
Crespo-Garcia, Ph.D., University of Montreal, Canada
Full presentations will be available on demand to ARVO
participants starting May 1, 2021 at 7:00 a.m. ET. The poster
presentation will also be available on the UNITY website under
Publications at this time.
About Diabetic Macular Edema Diabetic macular
edema (DME) is characterized by leaky blood vessels in the eye,
contributing to swelling of the retina and vision loss. The
National Eye Institute identifies DME as the most prominent
complication of diabetes and the leading cause of blindness in
working age individuals, impacting more than 20 million people
worldwide. However, nearly half of individuals with DME are
undiagnosed and of those that do get treated with the current
standard of care, a significant proportion of patients fail to
respond to treatment.
About UBX1325UBX1325, currently in Phase 1
clinical development, is a novel senolytic small molecule inhibitor
of Bcl-xL, a member of the Bcl-2 family of apoptosis regulatory
proteins. Bcl-xL is highly expressed in pathogenic blood vessels in
the retina, and UBX1325 has been shown to result in the selective
elimination of senescent cells, reduction in vascular leak and
restoration of healthy blood vessels in preclinical models. UBX1325
is currently being evaluated in clinical trials for the treatment
of age-related diseases of the eye, including diabetic macular
edema, diabetic retinopathy and age-related macular
degeneration.
About UNITYUNITY is developing
a new class of therapeutics to slow, halt or reverse diseases of
aging. UNITY’s current focus is on creating medicines to
selectively eliminate or modulate senescent cells and thereby
provide transformative benefit
in age-related ophthalmologic and neurologic diseases.
More information is available
at www.unitybiotechnology.com or follow us
on Twitter and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements including statements related to
UNITY’s understanding of cellular senescence and the role it plays
in diseases of aging, the potential for UNITY to develop
therapeutics to slow, halt, or reverse diseases of aging, including
for ophthalmologic and neurologic diseases, the potential for UNITY
to successfully commence and complete clinical studies of UBX1325
for DME, AMD, and other ophthalmologic diseases, the expected
timing of initial results of the Phase 1 study of UBX1325, the
timing of the expected commencement of the Phase 2a study of
UBX1325, and UNITY’s expectations regarding the sufficiency of its
cash runway. These statements involve substantial known and unknown
risks, uncertainties, and other factors that may cause our actual
results, levels of activity, performance, or achievements to be
materially different from the information expressed or implied by
these forward-looking statements, including the risk that
the COVID-19 worldwide pandemic may continue to
negatively impact the development of preclinical and clinical drug
candidates, including delaying or disrupting the enrollment of
patients in clinical trials, risks relating to the uncertainties
inherent in the drug development process, and risks relating to
UNITY’s understanding of senescence biology. We may not actually
achieve the plans, intentions, or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make. The
forward-looking statements in this press release represent our
views as of the date of this release. We anticipate that subsequent
events and developments will cause our views to change. However,
while we may elect to update these forward-looking statements at
some point in the future, we have no current intention of doing so
except to the extent required by applicable law. You should,
therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date of
this release. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of the Company in general, see UNITY’s
most recent Annual Report on Form 10-K for the year
ended December 31, 2020, filed with the Securities and
Exchange Commission on March 23, 2021, as well as other
documents that may be filed by UNITY from time to time with
the Securities and Exchange Commission.
MediaCanale CommunicationsJason Spark
Jason.spark@canalecomm.com
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Sep 2023 to Sep 2024